Korea Bio-Gen Co.Ltd (KQ:318000) — Stock Price
Korea Bio-Gen Co.Ltd (KQ:318000) is currently trading at ₩3050.00 KRW, up 2.52% today. Over the past 52 weeks, shares have ranged between ₩2595.00 and ₩5740.00. This page tracks Korea Bio-Gen Co.Ltd's live share price on the KQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Korea Bio-Gen Co.Ltd market capitalisation.
Korea Bio-Gen Co.Ltd (318000) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Korea Bio-Gen Co.Ltd's daily closing share price and trading volume on the KQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Korea Bio-Gen Co.Ltd Income Statement — Revenue, Profit & Earnings by Year
Korea Bio-Gen Co.Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | ₩23.92 Billion | ₩24.92 Billion | ₩21.59 Billion | ₩24.35 Billion | ₩27.20 Billion |
| Cost of Revenue | ₩16.77 Billion | ₩16.92 Billion | ₩14.38 Billion | ₩16.99 Billion | ₩17.98 Billion |
| Gross Profit | ₩7.15 Billion | ₩8.00 Billion | ₩7.21 Billion | ₩7.36 Billion | ₩9.22 Billion |
| Research & Development | ₩1.35 Billion | ₩1.23 Billion | ₩837.00 Million | ₩1.07 Billion | ₩1.18 Billion |
| SG&A | ₩736.52 Million | ₩3.08 Billion | ₩1.95 Billion | ₩2.01 Billion | ₩1.97 Billion |
| Total Operating Expenses | ₩20.93 Billion | ₩21.76 Billion | ₩17.28 Billion | ₩20.24 Billion | ₩22.67 Billion |
| Operating Income | ₩2.99 Billion | ₩4.02 Billion | ₩4.53 Billion | ₩4.11 Billion | ₩5.89 Billion |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | ₩8.91 Million | ₩4.60 Million | ₩4.60 Million | ₩4.60 Million | ₩5.76 Million |
| Income Before Tax | ₩3.07 Billion | ₩4.29 Billion | ₩5.59 Billion | ₩3.92 Billion | ₩4.72 Billion |
| Income Tax Expense | — | — | — | — | — |
| Net Income | ₩2.59 Billion | ₩3.77 Billion | ₩4.58 Billion | ₩3.25 Billion | ₩4.00 Billion |
Korea Bio-Gen Co.Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Korea Bio-Gen Co.Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | ₩52.35 Billion | ₩51.64 Billion | ₩45.95 Billion | ₩43.07 Billion | ₩42.00 Billion |
| Total Current Assets | ₩30.12 Billion | ₩27.82 Billion | ₩26.05 Billion | ₩26.20 Billion | ₩26.62 Billion |
| Cash & Equivalents | — | ₩4.71 Billion | ₩3.31 Billion | ₩1.77 Billion | ₩2.77 Billion |
| Short-term Investments | ₩13.45 Billion | ₩6.02 Billion | ₩12.00 Billion | ₩9.54 Billion | ₩9.72 Billion |
| Net Receivables | ₩4.36 Billion | ₩7.00 Billion | ₩5.03 Billion | ₩7.99 Billion | ₩8.38 Billion |
| Inventory | ₩8.61 Billion | ₩9.99 Billion | ₩5.44 Billion | ₩6.63 Billion | ₩5.41 Billion |
| Property, Plant & Equipment | — | ₩17.43 Billion | ₩13.32 Billion | ₩11.98 Billion | ₩9.96 Billion |
| Goodwill | — | — | — | — | — |
| Total Liabilities | ₩5.42 Billion | ₩6.73 Billion | ₩3.90 Billion | ₩8.13 Billion | ₩10.39 Billion |
| Total Current Liabilities | ₩4.51 Billion | ₩5.59 Billion | ₩3.38 Billion | ₩7.61 Billion | ₩4.72 Billion |
| Long-term Debt | — | — | ₩0.00 | ₩0.00 | ₩3.58 Billion |
| Net Debt | — | — | — | ₩2.00 Billion | ₩812.85 Million |
| Total Stockholder Equity | ₩46.93 Billion | ₩44.91 Billion | ₩42.05 Billion | ₩34.95 Billion | ₩31.61 Billion |
| Retained Earnings | ₩25.28 Billion | ₩23.27 Billion | ₩20.42 Billion | ₩17.14 Billion | ₩14.54 Billion |
Korea Bio-Gen Co.Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Korea Bio-Gen Co.Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₩7.34 Billion | ₩4.29 Billion | ₩9.47 Billion | ₩1.67 Billion | ₩3.09 Billion |
| Capital Expenditures | ₩462.42 Million | ₩5.12 Billion | ₩2.42 Billion | ₩2.29 Billion | ₩2.36 Billion |
| Free Cash Flow | ₩6.88 Billion | ₩-826.14 Million | ₩7.05 Billion | ₩-617.53 Million | ₩734.39 Million |
| Investing Cash Flow | — | ₩-2.02 Billion | ₩-6.03 Billion | ₩-1.85 Billion | ₩-8.08 Billion |
| Financing Cash Flow | — | ₩-937.58 Million | ₩-1.88 Billion | ₩-748.39 Million | ₩4.13 Billion |
| Dividends Paid | ₩-652.45 Million | ₩869.94 Million | ₩835.63 Million | ₩809.75 Million | ₩606.11 Million |
| Stock-Based Compensation | — | ₩5.57 Million | ₩21.17 Million | ₩15.72 Million | — |
| Depreciation | ₩1.56 Billion | ₩1.17 Billion | ₩896.77 Million | ₩766.76 Million | ₩662.75 Million |
| Change in Cash | ₩-1.30 Billion | ₩1.40 Billion | ₩1.54 Billion | ₩-996.80 Million | ₩-852.59 Million |
Korea Bio-Gen Co.Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track Korea Bio-Gen Co.Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Mar 31, 2026 | 87.61 | — | — |
| Dec 31, 2025 | 71.44 | — | — |
| Sep 30, 2025 | 45.04 | — | — |
| Jun 30, 2025 | 124.74 | — | — |
| Mar 31, 2025 | 56.71 | — | — |
| Dec 31, 2024 | 64.04 | — | — |
| Sep 30, 2024 | 59.76 | — | — |
| Jun 30, 2024 | 168.13 | — | — |